HIV and AIDS: Causes, Types, Immune Impact, and Treatment

AIDS (Acquired Immunodeficiency Syndrome) is the advanced stage of infection with Human Immunodeficiency Virus (HIV). Two main types exist:

  • HIV-1: Global pandemic strain; higher transmissibility, faster progression.
  • HIV-2: Endemic in West Africa; lower virulence, slower progression, intrinsic resistance to NNRTIs.

Pathogenesis

  • HIV targets CD4+ T-helper cells via gp120 binding to CD4 + CCR5/CXCR4 coreceptors.
  • Viral replication → CD4 depletion → loss of cell-mediated and humoral immunity.
  • Immune activation/inflammation drives non-AIDS comorbidities (cardiovascular, renal, neurocognitive).

Transmission

  • Sexual contact (vaginal, anal), blood exposure (needles, transfusions), perinatal (pregnancy, birth, breastfeeding).
  • Not transmitted by: Casual contact, saliva, sweat, tears, insects, air, water, surfaces.

Disease Stages

  1. Acute seroconversion: Flu-like illness 2–4 weeks post-exposure; high viremia.
  2. Clinical latency: Asymptomatic; CD4 declines slowly (years).
  3. AIDS: CD4 <200 cells/μL or AIDS-defining illness (opportunistic infections: PCP, TB, CMV, MAC, candidiasis; cancers: KS, lymphoma).

Treatment: Antiretroviral Therapy (ART)

  • Goal: Sustained viral suppression (<50 copies/mL) → immune recovery, near-normal lifespan, zero sexual transmission (U=U).
  • Regimens: 2 NRTIs + INSTI (preferred: bictegravir/tenofovir alafenamide/emtricitabine, dolutegravir/lamivudine).
  • Initiation: As soon as possible after diagnosis (rapid start).
  • Monitoring: Viral load, CD4, renal/hepatic function, lipid panel, adherence.

Prevention

  • PrEP (pre-exposure prophylaxis): TDF/FTC or TAF/FTC daily or event-driven.
  • PEP (post-exposure): 28-day ART within 72h.
  • TasP (treatment as prevention), harm reduction, VMMC, condom use.

Global 95-95-95 targets (diagnosed, on ART, suppressed) drive epidemic control. Stigma remains a barrier to testing and care.

HIV & AIDS - Related Articles